文献速递银屑病与炎症性皮肤病

司库奇尤单抗治疗TNF-α抑制剂失败银屑病患者的随机开放标签研究(SIGNATURE)

Secukinumab for patients failing previous tumour necrosis factor-α inhibitor therapy: results of a randomized open-label study (SIGNATURE).
PubMed 文献 · Br J Dermatol · 2019-12-25

SIGNATURE研究为随机开放标签非对照研究,纳入233例对TNF-α抑制剂疗效失败的的中重度斑块状银屑病患者,随机接受司库奇尤单抗300mg或150mg。

要点

  • TNF-α抑制剂失败的银屑病患者换用司库奇尤单抗仍可获得良好PASI 75应答
  • 300mg组持续治疗至72周时77%的患者维持PASI 75应答

核心结论

  • 司库奇尤单抗对既往TNF-α抑制剂疗效失败的中重度斑块状银屑病患者有效且安全性可接受。

研究设计与样本

  • 随机、开放标签、非对照研究,在英国和爱尔兰53个皮肤科中心开展。
  • 233例患者按1:1随机接受司库奇尤单抗300mg或150mg皮下注射,每周1次共4周,之后每4周1次。
  • 患者按既往TNF-α抑制剂疗效失败情况分层,仅纳入各时间点起始并维持同一剂量的患者进行疗效评估。

主要发现

  • 持续300mg治疗至72周时,77%(54/70)的患者达到PASI 75。
  • DLQI从基线至第16周改善,并维持至72周。
  • 安全性总体与既往司库奇尤单抗研究一致,但念珠菌感染等部分不良事件发生率较高。

关键数值与推荐

  • 72周时持续300mg组PASI 75应答率为77%(54/70)。

临床怎么用

  • 对于TNF-α抑制剂疗效失败的中重度斑块状银屑病患者,司库奇尤单抗可作为治疗选择。
  • 临床使用中需关注念珠菌感染等不良事件的发生。

局限性

  • 本研究为开放标签、非对照设计。
  • 疗效评估仅纳入各时间点起始并维持同一剂量的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Efficacy data on therapies for patients with psoriasis who have failed tumour necrosis factor (TNF)-α inhibitor therapy is limited. OBJECTIVES: To determine the effectiveness and tolerability of secukinumab, an interleukin (IL)-17A inhibitor, in patients with moderate/severe chronic plaque psoriasis with documented efficacy failure of TNF-α inhibitor therapy (SIGNATURE study). METHODS: This was a randomized, open-label, noncomparator study in 53 dermatology centres in the U.K. and Republic of Ireland. Patients were randomized 1 : 1 to receive secukinumab 300 mg or 150 mg subcutaneously every week for 4 weeks, then 4-weekly thereafter. Patients were stratified by their prior efficacy failure with TNF-α inhibitors. Only patients who started and stayed on the same dose at each time point were included for efficacy assessments. RESULTS: In total, 233 patients were analysed. The primary end point was met, with a statistically significant improvement in response rates [75% reduction in Psoriasis Area and Severity Index (PASI 75)] from baseline to week 16 in both secukinumab 300 mg and 150 mg dose groups [77 of 118 patients (65·3%) and 51 of 115 patients (44·3%), respectively; P < 0·0001]. After 72 weeks, in patients starting and remaining on 300 mg, 77% (54 of 70) achieved PASI 75. Improvements in Dermatology Life Quality Index from baseline to week 16 occurred and were maintained up to 72 weeks. The safety profile was generally consistent with previous secukinumab studies, although a higher incidence of some adverse events (e.g. candida infections) was observed. CONCLUSIONS: This study provides evidence of efficacy and safety of secukinumab for treatment of patients with psoriasis who failed prior TNF-α inhibitor therapy. This study represents a 'real-world' population, providing reassurance that secukinumab is a treatment option in this difficult-to-treat population. What's already known about this topic? Conventional systemic nonbiological and tumour necrosis factor (TNF)-α inhibitor therapies for plaque psoriasis have not fully met patients' needs. There is a lack of data to support the treatment pathways for patients with psoriasis who have inadequate responses to TNF-α inhibitor therapy. Secukinumab, a recombinant high-affinity fully human monoclonal anti-human interleukin-17A antibody of the IgG1/κ-class, has shown excellent safety and efficacy in the treatment of moderate-to-severe psoriasis. What does this study add? This is the first study evaluating treatment with biologics after prior efficacy failure of TNF-α inhibitor therapy as defined by the U.K. National Institute for Health and Care Excellence criteria. Secukinumab is an effective treatment in this difficult-to-treat patient population. This study provides important practical information for clinicians managing psoriasis. Adverse events were consistent with the phase III programme for secukinumab, although some adverse events, e.g. candida, were increased.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Warren RB, Barker JNWB, Finlay AY, et al. Secukinumab for patients failing previous tumour necrosis factor-α inhibitor therapy: results of a randomized open-label study (SIGNATURE). Br J Dermatol. 2019. PMID: 31628677. doi:10.1111/bjd.18623

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。